Gilead vet Alessan­dro Ri­va steers Glen­mark's biotech spin­off on in­de­pen­dent course

Alessan­dro Ri­va turned heads when he left his on­col­o­gy post at Gilead to front a new Glen­mark ven­ture. What was one of the in­dus­try’s top can­cer ex­ecs do­ing at a gener­ic drugs com­pa­ny?

“No­body knew — or few peo­ple knew — that Glen­mark had and has 400 peo­ple ded­i­cat­ed to in­no­va­tion,” Ri­va told End­points News. 

The in­no­va­tion arm is now try­ing to make its name known as it spins off from Glen­mark and launch­es to­day as Ich­nos Sci­ences. With a base in Para­mus, New Jer­sey, a bi­o­log­ics wing in Switzer­land and a new chem­i­cal en­ti­ty re­search branch in In­dia, Ich­nos will clin­i­cal­ly de­vel­op five mol­e­cules aimed at first in class treat­ments for can­cer, au­to-im­mune dis­or­ders and pain.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER